

Effectiveness of self-training with a web-based digital health application vs. physiotherapy in the treatment of disorders of the patella: a randomized controlled trial

Tobias Alexander Mayer, Daniel Koska, Ann-Kathrin Harsch, Christian Maiwald

Submitted to: Journal of Medical Internet Research
on: September 13, 2024

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript.....	5
Supplementary Files.....	37
.....	37
Figures	38
Figure 1.....	39
Figure 2.....	40
Figure 3.....	41
Figure 4.....	42
Figure 5.....	43
Figure 6.....	44
Multimedia Appendixes	45
Multimedia Appendix	46
Multimedia Appendix 0.....	46
Multimedia Appendix 0.....	46
Multimedia Appendix 1.....	46
Multimedia Appendix 2.....	46
Multimedia Appendix 3.....	46
Multimedia Appendix 4.....	46
Multimedia Appendix 5.....	46
Related publication(s) - for reviewers eyes onlies	47
Related publication(s) - for reviewers eyes only 0.....	47
Related publication(s) - for reviewers eyes only 0.....	47

Effectiveness of self-training with a web-based digital health application vs. physiotherapy in the treatment of disorders of the patella: a randomized controlled trial

Tobias Alexander Mayer¹ Dr rer nat; Daniel Koska¹ Dr rer nat; Ann-Kathrin Harsch¹ MSc; Christian Maiwald¹ Prof Dr

¹Department of Research Methodology and Data Analysis in Biomechanics Institute of Human Movement Science and Health Chemnitz University of Technology Chemnitz DE

Corresponding Author:

Tobias Alexander Mayer Dr rer nat
Department of Research Methodology and Data Analysis in Biomechanics
Institute of Human Movement Science and Health
Chemnitz University of Technology
Thüringer Weg 11
Chemnitz
DE

Abstract

Background: Disorders of the patella are among the most prevalent knee injuries. While exercise therapy is widely accepted as an effective treatment strategy, the positive effects of conventional exercise therapy under the guidance of a physiotherapist may be offset by inherent limitations such as difficulties in scheduling appointments or statutory policies restricting the number of training sessions. Home-based exercise interventions using digital health applications (DHA) may help address some of these limitations.

Objective: The aim of this study was to assess the efficacy of a 12-week exercise intervention utilizing a web-based DHA (Mawendo, Biberach, Germany) for improving knee function and/or reducing pain in patients with disorders of the patella (ICD-10 M22).

Methods: The outcomes of the DHA intervention group (IG DHA) were compared to a control group that received conventional physiotherapy covered by statutory health insurance in Germany (CG SHI-PT). A total of 259 patients with diagnosed disorders of the patella were included in the trial and randomly allocated to IG DHA (n=136) and CG SHI-PT (n=123). The trial was registered with the DRKS (German Clinical Trials Register; WHO Primary Register) under No. DRKS00023454.

Two primary endpoints were examined:

- 1) 'Knee function' (KOOSADL subscale, range 0-100 points (p))
- 2) 'Knee pain' (visual analogue scale, VAS, range 0-100 p)

Participants were asked to complete two surveys; one before the first therapy session (PRE) and one after completing the treatment period of 12 weeks (POST).

Results: Training with the DHA resulted in a 4.5-fold greater improvement in 'knee function' (PRE-POST differences in KOOSADL Score; IG DHA: 15.7 p (95 % CI [13.7; 17.6]) vs. CG SHI-PT: 3.5 p (95 % CI [1.5; 5.5])) and a 3.5-fold greater reduction in 'knee pain' (PRE-POST differences in VAS pain score; IG DHA: -22.5 p (95 % CI [-25.2; -19.9]) vs. CG SHI-PT: -6.5 p (95 % CI [-8.7; -4.4])) compared to SHI-PT. Only the improvements in IG DHA exceeded the limits of clinical relevance. The differences between the treatment groups (KOOSADL score -10.1 p (95 % CI [Inf; -8.0]), VAS pain score 14.3 p (95 % CI [11.7; Inf])) were statistically significant ($P < .001$) for both endpoints in favor of IG DHA. No effect was found for age or sex. The reported use of pain medication decreased substantially in IG DHA, and showed almost no change in CG SHI-PT.

Conclusions: Our findings indicate that the investigated DHA is superior to SHI-PT for treating disorders of the patella. DHA has therefore been approved by the German Federal Institute for Drugs and Medical Devices for the treatment of disorders of the patella in persons of all sexes aged 12 and over. Clinical Trial: The trial was registered with the DRKS (German Clinical Trials

Register; WHO Primary Register; <https://drks.de/search/de>) under No. DRKS00023454.

(JMIR Preprints 13/09/2024:66463)

DOI: <https://doi.org/10.2196/preprints.66463>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ **Please make my preprint PDF available to anyone at any time (recommended).**

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in <http://www.jmir.org>

No. Please do not make my accepted manuscript PDF available to anyone.

Original Manuscript

Original Paper

Authors

Dr. Mayer T A, Dr. Koska D, Harsch A-K & Prof. Dr. Maiwald C

Corresponding author: Dr. Mayer T A (tobias.mayer@hsw.tu-chemnitz.de)

Affiliation

Chemnitz University of Technology
Institute of Human Movement Science and Health
Research Methodology and Data Analysis in Biomechanics
Thüringer Weg 11
09126 Chemnitz
Germany

Effectiveness of self-training with a web-based digital health application vs. physiotherapy in the treatment of disorders of the patella: a randomized controlled trial

Abstract

Background: Disorders of the patella are among the most prevalent knee injuries. While exercise therapy is widely accepted as an effective treatment strategy, the positive effects of conventional exercise therapy under the guidance of a physiotherapist may be offset by inherent limitations such as difficulties in scheduling appointments or statutory policies restricting the number of training sessions. Home-based exercise interventions using digital health applications (DHA) may help address some of these limitations.

Objective: The aim of this study was to assess the efficacy of a 12-week exercise intervention utilizing a web-based DHA (Mawendo, Biberach, Germany) for improving knee function and/or reducing pain in patients with disorders of the patella (ICD-10 M22).

Methods: The outcomes of the DHA intervention group (IG DHA) were compared to a control group that received conventional physiotherapy covered by statutory health insurance in Germany (CG SHI-PT). A total of 259 patients with diagnosed disorders of the patella were included in the trial and randomly allocated to IG DHA (n=136) and CG SHI-PT (n=123). The trial was registered with the DRKS (German Clinical Trials Register; WHO Primary Register) under No. DRKS00023454. Two primary endpoints were examined: 'Knee function' (KOOS_{ADL} subscale, range 0-100 points (p)) and 'Knee pain' (visual analogue scale, VAS, range 0-100 p). Participants were asked to complete two surveys; one before the first therapy session (PRE) and one after completing the treatment period of 12 weeks (POST).

Results: Training with the DHA resulted in a 4.5-fold greater improvement in 'knee function' (PRE-POST differences in KOOS_{ADL} Score; IG DHA: 15.7 p (95 % CI [13.7; 17.6]) vs. CG SHI-PT: 3.5 p (95 % CI [1.5; 5.5])) and a 3.5-fold greater reduction in 'knee pain' (PRE-POST differences in VAS pain score; IG DHA: -22.5 p (95 % CI [-25.2; -19.9]) vs. CG SHI-PT: -6.5 p (95 % CI [-8.7; -4.4])) compared to SHI-PT. Only the improvements in IG DHA exceeded the limits of clinical relevance. The differences between the treatment groups (KOOS_{ADL} score -10.1 p (95 % CI [Inf; -8.0]), VAS pain score 14.3 p (95 % CI [11.7; Inf])) were statistically significant ($P < .001$) for both endpoints in favor of IG DHA. No effect was found for age or sex. The reported use of pain medication decreased substantially in IG DHA, and showed almost no change in CG SHI-PT.

Conclusions: Our findings indicate that the investigated DHA is superior to SHI-PT for treating disorders of the patella. DHA has therefore been approved by the German Federal Institute for Drugs and Medical Devices for the treatment of disorders of the patella in persons of all sexes aged 12 and over.

Keywords: M22; disorders of the patella; RCT; DiGA; physiotherapy; digital health application

Introduction

The knee is the second most common site for musculoskeletal pain[1], with 11-17% of the cases affecting the anterior knee or the patellofemoral joint area. Muscular dysfunctions are considered an important biomechanical cause of such patella-related disorders[2–4]. Therefore, exercise therapy is

widely regarded as an effective treatment strategy[4–8]. Conventional exercise therapy is typically administered on an outpatient basis under the guidance of a physiotherapist. The benefits of having a trained physiotherapist, however, may be offset by drawbacks such as difficulties in scheduling appointments or a limited number of training sessions available due to regulatory limitations of German statutory health insurance. Therefore, home-based exercise interventions may present a valid alternative, as they have been reported to be at least as effective as traditional physiotherapy in reducing patellofemoral pain[9] and improving knee function[10]. Kettunen et al.[11,12] found that an 8-week home exercise program was as effective as knee arthroscopy and an 8-week home exercise program together improving knee function and reducing pain. Similar findings have been reported for other knee conditions, such as meniscal tears[13–15], knee osteoarthritis[16,17], and other nonoperative knee conditions[18]. While unsupervised home-based exercise programs have demonstrated clinical effectiveness, they often lack structured feedback, personalization, and sustained engagement [19]. Frequent barriers to following physiotherapist-prescribed exercise programs also include limited social support, low self-efficacy, and a sense of helplessness [20]. These limitations have led to increased interest in digital health applications (DHA), which aim to address these gaps by delivering exercise therapy through interactive, software-based tools such as mobile apps or web-based platforms [21,22]. Compared to conventional physiotherapy, DHAs may also improve accessibility, especially for individuals with limited mobility or scheduling constraints [23,24], and enable more flexible and frequent engagement with exercise programs. Furthermore, they offer scalable, cost-effective solutions that can help alleviate healthcare resource limitations [25], as well as comprehensive possibilities to visualize exercises, educate about the condition in question, track training sessions and progress, which may boost individual training motivation. There is evidence that DHAs may achieve better efficacy than conventional home training, for example, in treating degenerative meniscal tears[26], low back pain[27], or shoulder disorders[28]. However, only a few randomized controlled trials (RCT) have compared DHAs directly to conventional physiotherapy covered by statutory health insurance (SHI-PT), and none of them have investigated patellar disorders. In Germany, the Digital Healthcare Act allows for DHAs to be covered by statutory health insurance once their efficacy is demonstrated. This encompasses device safety, data protection, as well as demonstrable benefits compared to standard care. Following this, DHAs have undergone rapid development in Germany since 2020. As of March 31, 2025, 40 applications have been permanently approved for prescription, while 19 applications have been preliminarily approved. This includes a number of DHAs for exercise therapy [29–32] that have been granted approval for coverage by German statutory health insurance. In this context, the present study aimed to evaluate the efficacy (improvement in knee function and/or pain) of a 12-week exercise intervention using a novel DHA (Mawendo, Biberach, Germany) compared to SHI-PT in patients with disorders of the patella (ICD-10 M22). The corresponding research question was: Is the novel DHA clinically superior to SHI-PT in improving knee function and/or reducing knee pain for ICD-10 M22 patients over a 12-week intervention period?

Methods

Ethics, study registration, and design

The pre-specified study protocol was approved and registered by the Institutional Ethics Committee of the Faculty of Behavioural and Social Sciences of the Chemnitz University of Technology (registration number: V-439-17-CM-MAWENDO-II-18042021) in agreement with current data protection regulations. The trial was registered with the DRKS (German Clinical Trials Register; WHO Primary Register) under No. DRKS00023454 for 14 different orthopedic ICD-10 indications. These 14 ICD-10 indications will be examined in 11 separate randomized controlled prospective clinical trials with two treatment groups. The present RCT is the first among the 11 RCTs to have completed treating the pre-specified number of patients. At the time of writing this manuscript, the

10 remaining RCTs are still in the stage of data collection. In this work, different strategies for treating diseases of the patella (ICD-10 M22) were compared between an active control group that received the current standard therapy in Germany (CG SHI-PT), and an intervention group using the DHA Mawendo (IG DHA). Participants and investigators were not blinded to the type of treatment or group allocation. All participants had to give written informed consent prior to enrollment in the study. The DHA Mawendo complies with all currently active data protection regulations and laws in Germany and Europe. The participants of the study did not receive any supplemental assistance with regard to the utilization of the DHA beyond what is generally provided.

Study population

The participants in this study were recruited by orthopedists (recruiters) during their regular consultation activities at orthopedic clinics and medical practices. Patients with confirmed disorders of the patella and internet access were eligible for participation. Children (age < 12 y) were not allowed to take part in the study. Adolescents (age < 18 y) required the consent of a legal representative. The patients were fully informed about the study by the attending orthopedist and received a study information sheet outlining the study's objectives, procedures, and treatment conditions (DHA vs. Physiotherapy, see appendix). The pain intensity level was assessed by the recruiter prior to study inclusion using a Verbal Numerical Rating Scale[33] (VNRS, value range 0-10). Patients with very low (VNRS pain intensity ≤ 2) or very severe pain (VNRS pain intensity ≥ 8) were excluded from the study to control for disease severity. The following illnesses or physical conditions were defined as exclusion criteria:

- (a) Knee surgery up to six months prior to the start of treatment
- (b) Severe or acute diseases of the cardiovascular system (e.g., acute myocardial infarction, acute ischemic heart disease, high blood pressure with heart failure, or hypertensive crisis)
- (c) Diseases of the lungs or respiratory tract (e.g., pneumonia, pulmonary embolism)
- (d) Tumor diseases (e.g., malignant neoplasm of the bone and articular cartilage, malignant neoplasm of internal organs)
- (e) Infection and fever (e.g., rheumatic fever, purulent arthritis, sepsis, bacterial infection)
- (f) Injuries or diseases of the musculoskeletal system outside the indication ICD-10 M22
- (g) Bleeding tendencies (history of increased bleeding or taking anticoagulant medication)
- (h) Mental disorders (e.g., acute psychosis)
- (i) Severe visual impairment
- (j) Pregnancy

The study data were analyzed according to the intention-to-treat principle. Therefore, the occurrence of an exclusion criterion during the study did not lead to the exclusion of participants from further data analysis. Data on additional patient characteristics, such as body mass index, activity level, duration of symptoms, type of patellar disorder, and previous therapies, were not collected, as the primary aim was to evaluate the effectiveness of the DHA in real-world conditions, where broad accessibility is prioritized over detailed subgroup analyses. Collecting only essential data for the primary analysis also helped minimize participant burden. Prior experience with digital devices was not assessed, as the intervention (DHA Mawendo) was designed to be intuitive and accessible regardless of technological familiarity.

Randomization

Participants were allocated to the treatment arms using simple randomization within the following strata:

- 1) Recruiter
- 2) Pain medication intake of maximum WHO level 1 (yes/no)

3) Baseline VNRS pain level (3 - 4 / 5 - 7)

Simple randomization was employed to impede the recruiter's ability to predict the sequence's order. Stratification by recruiter was implemented to account for potential variability in patient selection, initial assessments, and treatment initiation timelines across recruitment centers. This approach aimed to enhance internal validity and reduce confounding effects arising from differences in clinical judgment or regional healthcare structures. Current literature provided no evidence for potential bias between treatment arms for treatment history, stage of disease, age, or sex in previous studies, and thus did not include them as strata for randomization. A browser-based web application (Rek-app, Mawendo, Biberach, Germany) created specifically for recruiting purposes was provided to the recruiters. A set of 4 randomization lists (2 levels for pain medication $\times$ 2 levels for baseline VNRS pain) with 100 patients each was stored for each recruiter in the Rek-app. The statistical software R (version 3.6.2) was used to create these randomization lists [34]. The recruiters used the Rek-app to check exclusion criteria, include participants in the study, and randomly allocate participants to treatment arms according to the stored randomization lists (allocation sequence was concealed from the recruiters). Rek-app provided recruiters and participants with a participant-specific ID, through which the participants gained access to the web-based survey platform. A total of seven recruitment centers were involved with this study. Figure 1 provides a summary of the recruitment process.




Figure 1: Flow chart of recruitment, randomization, and data collection.

Intervention

The intervention for the active control group CG SHI-PT consisted of conventional physiotherapy

(Germany's current standard medical care), where participants selected their own physiotherapists and made their own appointments. IG DHA was treated using DHA Mawendo v1.6 (certified medical device, risk class 1) and used the DHA at any suitable location.

Treatment of CG SHI-PT

Physiotherapeutic treatment in Germany includes measures that can be prescribed according to the German Heilmittel-Richtlinie §92 Abs. 1 S2 No. 6 SGB V (German Therapeutic Products Guidelines, §92 Para. 1 Sentence 2 No. 6 Social Code V):

- preparation of an individual treatment plan
- assistance provided by the physiotherapist
- execution of physiotherapeutic measures on/with the patient
- standard treatment duration
- necessary rest following treatment
- progress documentation and, if necessary, progress report to the prescribing physician
- additional work and administrative tasks

Ideally, the first physiotherapy treatment session should include a medical history, pain localization and, if necessary, mobility tests. The physiotherapist then develops a therapy plan that is implemented in the subsequent sessions. This may include active and passive mobilization and strengthening exercises, or manual therapy. The number of sessions and prescriptions within the study period was determined by the treating orthopedist according to the current statutory health regulations in Germany. These permit 6 to 12 sessions during a 12-week treatment period, with up to 18 sessions allowed in severe cases.

Treatment of IG DHA

The DHA used in this study is a browser-based web application that provides digital exercise videos with self-explanatory exercise instructions, health information, and documentation options for self-administered home training (screenshots in appendix). Training sessions using the DHA contain sets of exercises lasting between 20-40 minutes, corresponding to the duration of a physiotherapy session. The user interface of the app includes the following sections: overview (1), education and information (2), therapy plan (3), and exercises (4).

In the overview section (1), users can record their training frequency and pain levels. Entries are used to feed a progress chart, which is used to track changes over time. The education and information section (2) contains information and educational material regarding the indication being treated. The therapy plan section (3) includes a therapy timeline, which is divided into three successive phases: basic, advanced, and stabilization. To ensure training progress and to avoid excessive demands, the 3 phases are designed to provide increasing exercise intensity and difficulty. The default duration of the 3 phases is 4 weeks. However, the prescribing doctor may adjust the duration of the phases to align the training program optimally with the patient's individual circumstances. In each phase, 8-16 exercises are provided (mobilization, coordination, strengthening, stretching, and massage), which should be performed 2 to 3 times a week during the treatment period of 12 weeks. The exercise section (4) provides instructional videos for the exercises to be performed by participants in their current therapy phase. An overview of available exercises in each phase including their objectives is presented in the appendix of this paper. Generally, the exercises for the various medical indications of DHA Mawendo are selected and compiled in accordance with the guidelines established by scientific medical societies and other scientific studies [35–54]. A systematic literature review is conducted for each medical indication on a biennial basis, under the supervision of an orthopedic surgeon, to ensure that the content of DHA aligns with the most recent scientific findings. A total of 215 articles were identified as relevant for the compilation of exercises for M22. These articles were

then systematically analyzed for practical relevance. The list of articles relevant to the ICD10-M22 exercises can be found in the appendix. For IG DHA, the treating orthopedist selected the training program in the DHA for the 12-week treatment period, with the option to deselect exercises deemed unsuitable for the patient. Participants could initiate their treatment immediately after recruitment.

Outcome measures

Two primary endpoints were examined in this study:

- 1) Improvement in 'knee function'
- 2) Reduction of 'knee pain'

Both endpoints describe different aspects of positive treatment effects and were therefore considered to be equally valid to assess medical benefit. The study was designed to evaluate therapeutic superiority of the DHA over SHI-PT in at least one of the two endpoints to comply with regulations given by the Federal Institute for Drugs and Medical Devices in Germany (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM).

The endpoints were assessed using an electronic questionnaire accessible using a web browser and an internet connection. The questionnaire was hosted and operated independently from any IT infrastructure associated with the DHA.

Participants were asked to complete a survey twice during the course of the study:

PRE: Before the first training session with DHA or the first physiotherapy treatment.

POST: After completing the 12-week treatment period.

Participants received the survey URL by email at the specified times and were reminded a maximum of three times by email to complete the pending questionnaires.

The endpoint 'knee function' was quantified using the German version of the Patient Reported Outcome (PRO) KOOS (Knee Injury and Osteoarthritis Outcome Score)[55]. KOOS is a validated questionnaire that measures aspects of health and functional status in diseases and injuries of the knee joint using 5 scales ('Pain', 'Symptoms', 'Activities of daily Living', 'Functionality in sports and leisure', 'Quality of life-related to the affected knee'). The 'Activities of daily Living' (KOOS_{ADL}) subscale was used to represent 'knee function'. The KOOS_{ADL} score is calculated from the 17 ADL items, with each item scored from best (0 p) to worst (4 p). A KOOS_{ADL} score of zero p represents extreme knee problems and 100 p represents no knee problems.

$$KOOS_{ADL} = 100 - \frac{\frac{1}{n} \sum_{i=1}^{n=17} ItemScore_i * 100}{4}$$

The endpoint 'knee pain' was assessed using a separate pain score based on a visual analogue scale (VAS, range 0-100 p, where 100 p represents worst pain imaginable). Participants were asked to quantify the intensity of their pain over the past week[56].

Adherence

In addition to the primary outcome measures, adherence was assessed through self-reported data collected via the web-based survey platform at the end of the intervention period. Participants in both

groups were asked to indicate how many of the prescribed therapy sessions they completed, selecting from predefined response categories: “All sessions completed”, “Almost all sessions completed”, “More than half completed”, “Half completed”, or “Fewer than half completed”.

Medication

Participants were asked to report whether they were using medication, including pain medication, before (PRE) and after the intervention (POST). However, no further details on medication frequency, or dosage were collected. A list of all reported pain medications is included in the appendix.

Safety Monitoring and Concomitant Care

Safety and adverse events were assessed through self-reported data collected via the web-based survey platform in the POST questionnaire. Participants were specifically asked whether any exclusion criteria had emerged during the treatment phase. These included severe or acute cardiovascular diseases, respiratory disorders, malignancies, infections, fever, musculoskeletal injuries or disorders unrelated to the training program, bleeding tendencies, psychiatric disorders, pregnancy, or other similar physical impairments. Additionally, participants reported whether they had undergone surgery related to the diagnosed condition (ICD-10 M22). However, no information was available regarding whether adverse events were directly attributable to the respective therapy.

Concomitant care was assessed using the PRE and POST questionnaires. Participants were asked whether they used additional therapies, such as acupuncture, and if so, they could list up to 10 additional therapies.

Sample size

Due to multiple testing (one hypothesis for each of the two primary endpoints), the significance level was adjusted using the Bonferroni method and set at $\alpha = .0125$ (one-sided testing). The minimal clinically important difference (MCID) was used as the effect size to be detected, and a power of $1 - \beta = .9$ was specified to calculate the required sample size for a superiority scenario. MCIDs for both outcomes were determined from several studies (KOOS_{ADL}: 10 p (sd = 15 p) [57–59], VAS: 10 p (sd=22 p) [56,60,61]). This resulted in sample sizes of $n=56$ (KOOS_{ADL}) and $n=121$ (VAS). The more conservative (larger) sample size of $n=121$ was used to generate sufficient statistical power for both endpoints. Sample sizes were determined using the SampleSize4ClinicalTrials R package[62].

Statistical analysis

Hypothesis tests were performed on null hypotheses of DHA not providing superior medical benefit in either one of the endpoints compared to SHI-PT.

A linear model (ANCOVA) was used to determine the effectiveness of DHA for both endpoints. The outcome score in the respective endpoint (‘knee function’, ‘knee pain’) at POST was used as the dependent variable, the treatment group as the predictor variable, and the PRE score as a covariate. The strata ‘recruitment center’, ‘pain medication intake’, and ‘VNRS pain level’ were used as control variables. Type II sum of squares were used due to simple randomization and unbalanced group sizes. For missing values in either PRE or POST the Missing at Random (MAR) assumption was assumed to be valid. These missing values were imputed using the jump to reference method (J2R, R package RefBasedMI [63,64]). The J2R method was selected for its ability to mitigate the risk of overestimating the efficacy of the intervention group. This approach is characterized by its conservatism and robustness in handling missing data in RCTs. For KOOS_{ADL}, the imputations were executed at item level and the total KOOS_{ADL} score was calculated for each of 50 imputations (reference group: SHI PT, covariates: 'recruitment center', 'pain medication intake', and 'VNRS pain

level'). Implausible values less than 0 resulting from the J2R imputation were replaced by the value 0 and floating point numbers were rounded to integers. Variables that were not required for the inferential statistical analysis of the two primary clinical endpoints, such as adherence data or information on additional therapies, were not imputed.

The model assumptions of the ANCOVA models of both outcomes were checked graphically for all 50 imputed datasets and were met sufficiently. The `mi.anova` function of the R package `miceadds`[65] was used to calculate the pooled ANCOVA tables. All analyses were performed using the statistical software R (version 4.2.3)[66].

Non-pre-specified additional analyses

In addition to the pre-specified ANCOVA analysis, exploratory statistical analyses were conducted to further examine potential intervention differences for the categorical factor "sex," and the numerical covariate "age" [67–73]. Apart from that, descriptive analyses were performed to better illustrate the relationship between PRE scores, and treatment success (POST – PRE difference), as well as recruiter-specific effects (statistically significant covariates). To this end, a scatter plot was generated to examine the association between PRE scores and treatment success (POST – PRE). Furthermore, a difference plot was employed to illustrate the distribution of treatment success across different recruiters.

Results

Participants and adherence (self-reporting)

259 participants were recruited between November 10, 2021 and January 21, 2023, and randomly assigned to either IG DHA or CG SHI-PT. IG DHA (n=136) received treatment using the DHA while CG SHI-PT (n=123) received SHI-PT. Six participants (IG DHA: n = 4, CG SHI-PT: n = 2) provided no survey data despite several e-mail inquiries. These participants were assumed to be missing completely at random and excluded from further analysis. Subsequently, data from 253 participants (IG DHA: n= 132; CG SHI-PT: n = 121) were analyzed. Another 6 of the remaining 253 participants provided incomplete datasets (IG DHA: n = 1; CG SHI-PT: n = 5; assumption missing at random): one participant did not provide PRE data, and 5 participants were lost to follow-up (POST data missing). These missing data were imputed for the inferential statistical analysis (jump to reference, J2R)[74]. Figure 2 summarizes the above information in a flowchart according to Consolidated Standards of Reporting Trials (CONSORT) [75].




Figure 2: Study flowchart according to CONSORT[75].

Demographic and clinical characteristics of IG DHA and CG SHI-PT are listed in Table 1.

Table 1: Demographic and clinical characteristics of IG DHA and CG SHI-PT

	IG DHA	CG SHI-PT
n participants	132	121
Sex	m: 71, f: 59, not specified: 2	m: 74, f: 44, not specified: 3
Mean age (sd)	35.4 (14.4) y	36.8 (12.1) y
Pain medication upon enrollment	yes: 34 , no: 98	yes: 37 , no: 84
Pain level upon enrollment (0 - 10)	3-4: 78, 5-7: 54	3-4: 72, 5-7: 49

118 out of 132 participants in IG DHA and 103 out of 121 participants in CG SHI-PT reported completing 'all' or 'almost all' treatment sessions. Additional adherence data can be found in Table 2.

Table 2: Number of completed treatment sessions

	IG DHA	CG SHI-PT
All	84 (63.6 %)	94 (77.7 %)
Almost all	34 (25.8 %)	9 (7.4 %)
More than half	12 (9.1 %)	8 (6.6 %)
Half	0 (0 %)	2 (1.7 %)
Not specified	2 (1.5 %)	8 (6.6 %)

Two participants (IG DHA: n=1, CG SHI-PT: n=1) reported a change in therapy during the course of the study due to time restrictions (IG DHA) and supplementary medication (CG SHI-PT). Three participants in CG SHI-PT reported the occurrence of one or more exclusion criteria during the treatment phase. Two participants reported an infection during treatment (answer option 'Infections and fever (e.g., rheumatic fever, purulent arthritis, sepsis, bacterial infections)') and one participant reported an unspecified mental disorder (answer option 'Mental disorders (e.g., acute psychosis)').

Primary endpoint 'knee function' (KOOS_{ADL} score)

In IG DHA, the pooled mean KOOS_{ADL} score improved from 66.2 p (95 % CI [64.3 p; 68.1 p]) to 81.9 p (95 % CI [80.3 p; 83.5 p]) from PRE to POST. This corresponds to an improvement in 'knee function' of 15.7 p (95 % CI [13.7 p; 17.6 p]).

In CG SHI-PT, 'knee function' (pooled mean KOOS_{ADL} score) improved by 3.5 p (95 % CI [1.5 p; 5.5 p]) from 70.4 p (95 % CI [68.3 p; 72.5 p]) PRE to 73.9 p (95 % CI [71.5 p; 76.3 p]) POST.

Training with DHA resulted in a 4.5 times greater improvement in 'knee function' compared to SHI-PT. Figure 3 illustrates this result using the imputed data set with the largest effect for CG SHI-PT. Table 3 summarizes the results of the primary endpoint 'knee function'.




Figure 3: PRE – POST comparison of KOOS_{ADL} score using notched boxplots (95% CI of median) including mean with 95% CI of the largest imputed effect in CG SHI-PT. Intra-individual positive treatment effects are blue, negative or no effects are red.

Table 3: KOOS_{ADL} pooled mean scores and corresponding 95% CI

Knee function (KOOS _{ADL} score in p)			
	PRE	POST	Difference POST-PRE
IG DHA	66.2 [64.3; 68.1]	81.9 [80.3; 83.5]	15.7 [13.7; 17.6]
CG SHI-PT	70.4 [68.3; 72.5]	73.9 [71.5; 76.3]	3.5 [1.5; 5.5]

The difference in KOOS_{ADL} score between IG DHA and CG SHI-PT (factor 'Intervention') was estimated at -10.1 p [Inf; -8.0 p] (adjusted one-sided 95 % CI, see Table 5) by the pooled ANCOVA and was statistically significant ($P < .001$, see Table 4).

Table 4: ANCOVA 'knee function'

R² = .389						
	SSQ	df1	F	P	eta ²	partial eta ²

KOOS _{ADL} score PRE	6890.216	1	63.479	< .001	.186	.234
Intervention	6391.123	1	67.002	< .001	.173	.221
Recruiter	983.384	6	1.256	.275	.027	.042
Pain medication	74.278	1	.785	.376	.002	.003
Pain level	28.946	1	.266	.606	.001	.001
Residual	22584.157	NA	NA	NA	NA	NA

Table 5: ANCOVA 'knee function' pooled estimates with adjusted one-tailed 95 % CI

term	coefficient	SE	lower 95 % CI	upper 95 % CI
(Intercept)	48.512	4.965	40.310	Inf
KOOS _{ADL} score PRE	.478	.071	.361	Inf
Intervention SHI-PT	-10.070	1.264	Inf	-7.984
Recruiter_C1	-9.584	9.730	Inf	6.482
Recruiter_D1	-6.576	3.851	Inf	-.209
Recruiter_E1	3.182	1.873	.088	Inf
Recruiter_F1	5.657	6.931	-5.788	Inf
Recruiter_G1	.547	5.069	-7.824	Inf
Recruiter_H1	-.232	5.657	Inf	9.109
Pain medication: no	1.442	1.458	-.965	Inf
Pain level: 5-7	.757	1.465	-1.662	Inf

Primary endpoint 'knee pain' (VAS pain score)

In IG DHA, the pooled mean VAS pain score decreased from 48.2 p (95 % CI [46.1 p; 50.3 p]) to 25.6 p (95 % CI [23.5 p; 27.8 p]) from PRE to POST. This corresponds to an improvement in 'knee pain' of -22.5 p (95 % CI [-25.2 p; -19.9 p]).

In CG SHI-PT, pooled mean VAS pain score improved by -6.5 p (95 % CI [-8.7 p; -4.4 p]) from PRE 44.7 p (95 % CI [42.4 p; 47.1 p]) to POST 38.2 p (95 % CI [35.3 p; 41.0 p]).

Thus, training with the DHA resulted in a 3.5 times greater reduction in 'knee pain' compared to SHI-PT. Figure 4 illustrates this result using the imputed data set with the greatest effect for CG SHI-PT. Table 6 summarizes the VAS pain score results of the primary endpoint 'knee pain'.




Figure 4: PRE – POST comparison of VAS pain score using notched boxplots (95% CI of median) including mean with 95% CI of the largest imputed effect in CG SHI-PT. Intra-individual positive treatment effects are blue, negative or no effects are red.

Table 6: VAS pain pooled mean scores and corresponding 95% CI

Knee pain (VAS pain score in p)			
	PRE	POST	Difference POST – PRE
IG DHA	48.2 [46.1; 50.3]	25.6 [23.5; 27.8]	-22.5 [-25.2; -19.9]
CG SHI-PT	44.7 [42.4; 47.1]	38.2 [35.3; 41.0]	-6.5 [-8.7; -4.4]

In the pooled ANCOVA for VAS pain score, the group difference between IG DHA and CG SHI-PT (factor 'intervention') was estimated at 14.3 p [11.7 p; Inf] (adjusted one-sided 95 % CI, see Table 8), and was also statistically significant ($P < .001$, see Table 7).

Table 7: ANCOVA 'knee pain'

$R^2 = .392$						
	SSQ	df1	F	P	eta ²	partial eta ²

VAS pain score PRE	8395.020	1	51.784	< .001	.138	.185
Intervention	12855.179	1	82.779	< .001	.211	.258
Recruiter	2259.651	6	2.185	.041	.037	.058
Pain medication	214.351	1	1.391	.238	.004	.006
Pain level	164.886	1	.974	.324	.003	.004
Residual	36984.465	NA	NA	NA	NA	NA

Table 8: ANCOVA 'knee pain' pooled estimates with adjusted one-tailed 95 % CI

term	coefficient	SE	lower 95 % CI	upper 95 % CI
(Intercept)	5.629	4.319	-1.504	Inf
VAS pain score PRE	.441	.084	.302	Inf
Intervention SHI-PT	14.328	1.596	11.692	Inf
Recruiter_C1	5.349	12.451	-15.210	Inf
Recruiter_D1	7.618	4.683	-.117	Inf
Recruiter_E1	-6.155	2.165	Inf	-2.579
Recruiter_F1	-3.658	8.825	Inf	10.913
Recruiter_G1	-2.330	6.519	Inf	8.435
Recruiter_H1	8.950	7.263	-3.043	Inf
Pain medication: no	-1.719	1.861	Inf	1.355
Pain level: 5-7	2.018	2.041	-1.353	Inf

Pain medication & concomitant care

During the course of the intervention, the reported use of pain medication decreased substantially in IG DHA (PRE: 35 (26.5 %), POST: 4 (3 %)), while it remained almost unchanged in CG SHI-PT (PRE: 37 (30.6 %), POST: 36 (27.3 %)), see Table 9. Only few participants provided no information on pain medication usage (PRE CG SHI-PT: n=1, POST IG DHA: n=1, POST CG SHI-PT: n=4).

Table 9: Number of participants using pain medication

	PRE	POST	Difference POST-PRE
IG DHA	35 (26.5 %)	4 (3.0 %)	-31 (-22.5 %)
CG SHI-PT	37 (30.6 %)	33 (27.3 %)	-4 (-3.3 %)

The following Table 10 enumerates the patients who received concomitant care during the course of the study. In the IG DHA group, no patient utilized additional physiotherapy. In contrast, one patient in the CG SHI PT group underwent additional physiotherapy sessions. The other concomitant therapies were as follows: ultrasound therapy, shock wave therapy, (cortisone) injection into the knee, massage, strengthening exercises, yoga and meditation.

Table 10: Number of participants using concomitant care

	PRE	POST	Difference POST-PRE
IG DHA	4 (3.0 %)	1 (.8 %)	-33 (-2.2 %)
CG SHI-PT	5 (4.1 %)	4 (3.3 %)	-2 (-.8 %)

Non-pre-specified additional analyses

After extending the ANCOVA models with the factor 'sex' and the covariate 'age' (numerical), including interaction effects with factor 'intervention', no statistically significant isolated effect of either 'sex' or 'age' on 'knee function' and 'knee pain' was found (P ranging from .28 to .91; see Table 11 - Table 12). The effect sizes (partial η^2) of 'sex' and 'age' are negligible and explain almost no additional variance compared to the statistical models without these factors/covariates (see Table 11 - Table 12).

For the interaction effects 'intervention:age' and 'intervention:sex', again no statistically significant effect was found for either endpoint (P ranging from .48 to .74; see Table 11 - Table 12). The effect sizes (partial η^2) of the two interaction effects can be described as negligible and provide almost no additional explanation (see Table 11 - Table 12).

Table 11: ANCOVA 'knee function' with the factor 'sex' and the covariate 'age' (numerical), including interaction effects with factor 'intervention'

R² = .402						
	SSQ	df1	F	P	eta²	partial eta²
KOOS _{ADL} score PRE	6851.619	1	62.332	< .001	.189	.240
Intervention	6548.347	1	68.131	< .001	.180	.232
Sex	4.004	1	.028	.868	< .001	< .001
Age	79.046	1	.786	.375	.002	.004
Recruiter	845.762	6	1.093	.364	.023	.037
Pain medication	99.632	1	1.046	.306	.003	.005
Pain level	106.118	1	1.038	.308	.003	.005
Intervention:Sex	13.906	1	.112	.738	< .001	.001
Intervention:Age	46.122	1	.440	.507	.001	.002
Sex:Age	2.104	1	.012	.912	< .001	< .001
Intervention:Sex:Age	4.034	1	.028	.867	< .001	< .001
Residual	21732.292	NA	NA	NA	NA	NA

Table 12: ANCOVA 'knee pain' with the factor 'sex' and the covariate 'age' (numerical), including interaction effects with factor 'intervention'

R² = .405						
	SSQ	df1	F	P	eta²	partial eta²
KOOS _{ADL} score PRE	8309.270	1	50.873	< .001	.139	.190
Intervention	13146.396	1	84.324	< .001	.220	.270
Sex	2.885	1	.013	.911	< .001	< .001
Age	185.610	1	1.177	.278	.003	.005
Recruiter	2075.138	6	2.013	.060	.035	.055
Pain medication	249.414	1	1.612	.204	.004	.007
Pain level	38.459	1	.176	.675	.001	.001
Intervention:Sex	28.349	1	.167	.683	< .001	.001
Intervention:Age	82.436	1	.506	.477	.001	.002
Sex:Age	43.666	1	.268	.605	.001	.001

Intervention:Sex:Age	5.144	1	.022	.883	< .001	< .001
Residual	35484.314	NA	NA	NA	NA	NA

For descriptive analysis of both statistically significant covariates (PRE score & Recruiter), the relationship between PRE scores, and treatment success (POST – PRE scores), as well as recruiter-specific effects (treatment success across different recruiters) are displayed for both endpoints in Figure 5 and Figure 6.




Figure 5: Relationship between PRE score and treatment success. Differences POST – PRE for both endpoints: A - 'knee function', B - 'knee pain'. IG DHA data are white, CG SHI-PT data are gray.




Figure 6: Treatment success (difference POST – PRE) for both endpoints across all recruiters; A - ‘knee function’ by recruiter. B - ‘knee pain’ by recruiter. IG DHA data are white, CG SHI-PT data are gray.

Discussion

Primary outcomes

This study provides evidence of the clinical superiority of DHA over SHI-PT for both primary endpoints, 'knee function' (KOOS_{ADL} score) and 'knee pain' (VAS pain score).

Knee function

The improvement achieved by IG DHA in our study (15.7 p KOOS_{ADL} score) not only meets the criterion of clinical relevance, but also that of 'substantial clinical benefit', suggested by several previous studies[57,59,76]. The improvement through SHI-PT was 4.5 times lower than in IG DHA and did not reach clinical relevance in our study.

Previous uncontrolled research on the efficacy of the Mawendo DHA reported a 14% improvement in the Kujala score over 12 weeks [10]. In the present study, 'knee function' improved by 23.7% in IG DHA compared to 4.8% in CG SHI-PT, further underscoring the effectiveness of the DHA. Regarding the external validity of our findings, Companion patella a similar DHA for ICD-10 M22 conditions was also evaluated against SHI-PT in a multicenter, prospective RCT. This study is particularly relevant as it was also conducted within the German healthcare system. The authors found DHA to be superior to SHI-PT in improving knee function, as assessed using the Kujala score (+8.68 p (95% CI [+3.74 p; +13.62 p], $P < .001$). The study, including its results, is listed in the DiGA directory of the German Federal Institute for Drugs and Medical Devices [30], indicating that it underwent thorough regulatory review. Although no further studies were identified that directly compare DHA to SHI-PT, other research supports the general efficacy of home-based exercise interventions for treating patellar conditions. Hong et al. examined the effectiveness of a six-week home-based exercise program combined with health education via remote support in patients with patellofemoral pain [77]. Their RCT (control group health education) found that this approach improved function by 14.6 %, as measured by the Anterior Knee Pain Scale (control group by 2.4 %, between-group difference, 9.0 (95%CI [4.1, 13.9], $P < .01$). Similarly, Nilmart et al. reported that a four-week telehealth-based therapeutic exercise program with real-time supervision significantly enhanced various functional parameters in patients with patellofemoral pain. In contrast, the control group, which engaged in self-guided stretching exercises, exhibited minimal change [78]. Additionally, Mecklenburg et al. [58] compared a 12-week 'Digital Care Program for Chronic Knee Pain' to an education-only control group and observed a 17% reduction in KOOS-PS score in IG DHA, compared to only 3.7% in CG SHI-PT. The difference between the intervention and control groups was -7.2 p (95% CI [-11.5 p; -3 p], $P = .001$), further demonstrating the potential benefits of digitally assisted home exercise programs.

Knee pain

The pain reduction of 22.5 p (VAS pain score) in IG DHA classifies as clinically relevant, and as substantially clinically beneficial[60,61]. We observed no clinically relevant effects for pain reduction through SHI-PT in our study. The achieved reduction in 'knee pain' using the Mawendo DHA was 47% compared to 14 % through SHI-PT.

Using the same DHA and treatment period as in the current study, Kölle et al.[10] reported a 64% reduction in knee pain on a knee pain VAS. Other studies investigating DHA interventions for patellofemoral pain support these results. DHA companion Patella demonstrated significant and clinically relevant pain reduction on a numeric pain rating scale (between-group difference, -1.50 (95%CI [-2.18, -.81], $P < .001$) [30]. Additionally, Hong et al. found improved pain outcomes (pain reduction up to 51.6 %) for home-based exercise program with health education using a VAS 01 – 100 mm (worst pain reduction, between-group difference, -19.3 (95%CI [-23.2, -15.5], $P < .01$ and pain with daily activity, between-group difference, -22.9 (95%CI [-28.3, -17.4], $P < .01$) [77]. In

comparison, the reduction in knee pain in the control group was minimal at a maximum of 5.2 % [77]. Nilmart et al. reported that a four-week telehealth-supervised therapeutic exercise program significantly reduced VAS pain (0 – 10 cm) by 67.3 % in patients with patellofemoral pain (-3.7 cm (95%CI [-4.2 cm, -3.3 cm], $P < .001$) [78]. In contrast, the control group (self-guided stretching) exhibited minimal change (-.1 cm (95%CI [-.8 cm, +.4 cm], $P = .801$) [78]. Similar patterns have been observed for DHAs in other orthopedic conditions. Toelle et al. found a 47% reduction in back pain using the Kaia DHA versus 37% for physiotherapy, while Weise et al. [23] reported a 53.1% reduction in back pain using the Vivira DHA versus 14.6% for physiotherapy. These findings reinforce the effectiveness of structured remote exercise programs in managing musculoskeletal pain. Together, these studies underscore the mounting evidence base supporting the utilization of DHA-assisted interventions for enhancing knee function and alleviating pain.

Comparison of treatment arms

We found large between-group differences for both endpoints in our study. One reason may be different treatment strategies used by different physiotherapists. Furthermore, an earlier start of treatment is associated with faster healing [79–82], and problems scheduling timely appointments may in turn limit the efficacy of SHI-PT. In comparison, self-managed training using a DHA can begin immediately after being prescribed by a doctor and eliminates the need for travel, further anamnesis, and potential waiting for appointments. DHAs also allow for significantly more treatment sessions during a 12-week intervention period, since the German regulations usually limit SHI-PT to 6 to 12 physiotherapy sessions (maximum 18 sessions) during the same period. In IG DHA patients should exercise 2-3 times per week. Since self-reported adherence was comparable between IG DHA and CG SHI-PT, patients in IG DHA received at least roughly twice the number of therapy sessions compared to CG SHI-PT. We hypothesize the greater training frequency to be one of the causal reasons for the significantly greater treatment success of DHA compared to SHI-PT. The actual start of treatment after diagnosis and the exact treatment frequency were not recorded in the present study. Further research should therefore address the relationship between onset of treatment, treatment frequency, and therapy success using DHAs.

Further benefits of DHA

In both treatment arms, around 30 % of patients used pain medication at PRE. Pain medication rate at POST decreased substantially to 3.0 % for IG DHA, but remained largely unchanged in CG SHI-PT. The reduction in pain medication corresponds to the greater pain reduction achieved in IG DHA. Therefore, DHA may also have indirect beneficial health effects by limiting the risk of pain medication (WHO level 1), such as NSAID-induced side effects and associated costs (NSAID, non-steroidal anti-inflammatory drug).

Statistically significant covariates in the ANCOVA

As expected, a statistically significant effect of the PRE scores was found for both endpoints [83]. Accordingly, participants with a worse PRE score tended to achieve greater improvements (Figure 5). The distribution of PRE scores, however, was similar in both treatment groups (IG DHA, CG SHI-PT), indicating a limited risk of confounding. The control variable 'recruiter' showed a statistically significant effect on the endpoint 'knee pain', while not being statistically significant on the endpoint 'knee function'. Our statistical modeling results suggest that recruiting facilities affect treatment effectiveness. This effect is subject to a high degree of uncertainty, as recruiting performance across the seven recruiting centers in our study varied considerably. 93 % of all participants were recruited by two recruiting centers, while the remaining centers only acquired 1-8 participants, each. This suggests that this effect stems from small subsamples, which are more likely to produce extreme results. Figure 6 illustrates the distribution of treatment success (mean difference

POST – PRE) in both endpoints across all recruiters, for the endpoint ‘knee pain’, slightly lower recruiter variances led to statistical significance in our ANCOVA model ($P = .041$).

Adherence, change of therapy & concomitant care

In both treatment arms, self-reporting revealed a comparably high level of adherence: 89.4% of IG DHA patients and 85.1% of CG SHI-PT patients attended ‘all’ or ‘almost all’ therapy sessions. Thus, treatment frequency, and not adherence, may provide a better explanation for the between-group differences found in our study. In addition, similar treatment changes occurred in both treatment arms (1 participant in each group; no information for 2 participants in DHA, and 7 participants in SHI-PT). We found a slightly larger POST dropout rate in SHI-PT (4 in SHI-PT vs. 1 in DHA). The reasons for this are speculative and may include the above-mentioned scheduling and travel required for SHI-PT. In both treatment groups, the number of patients receiving concomitant care was minimal. No patient in the IG DHA group utilized additional physiotherapy, and the other concomitant therapies were comparable between IG DHA and CG SHI-PT. Consequently, any potential bias attributable to concomitant care is highly improbable.

Possible limitations of the study

While we controlled for ‘recruiter’, ‘pain medication’, and ‘pain level’ in the ANCOVA model, there may be further confounding variables that were not considered in the model or during randomization. Since we found no evidence for possible bias of treatment effects due to age and sex of the participants, we did not include these covariates in the pre-specification of the statistical analysis. The distribution of age and sex in the treatment arms is comparable, suggesting that none of these variables had a systematic influence on the results. For confirmation purposes, the pre-specified ANCOVA model was exploratively extended for both endpoints to include the covariates age and sex. We found no evidence of relevant effects of age or sex on either endpoint, including interactions with intervention. It can therefore be concluded that neither age nor sex has a statistically significant effect on the efficacy of the IG DHA and CG SHI-PT interventions [67–73].

Blinding was not feasible in this study, as the nature of the interventions made it impossible to conceal the treatment strategy from participants or recruiters. A placebo app was not implemented, as BfArM guidelines for the evaluation of DHAs require evidence of superiority over usual care (SHI-PT in Germany), which does not include any additional DHA. A potential concern related to the lack of blinding is expectancy effects, where participants using the DHA may have rated the DHA systematically better due to its structured progression, interactive feedback, or perceived novelty compared to conventional physiotherapy. However, any resulting bias is likely limited, as all outcome measures were based on standardized, validated patient-reported outcome scores. The study did not include direct inquiries regarding the perceived quality of the intervention. While self-reported outcomes inherently carry the risk of expectancy effects, these instruments are widely used in clinical research and have established validity and reliability in similar patient populations. All outcomes in this study were assessed using validated patient-reported instruments (KOOS_{ADL}, VAS). Patients in both groups completed the surveys independently via a web-based platform, minimizing the potential for interviewer and social desirability bias. However, the use of self-reported measures introduces an unquantifiable risk of bias, particularly in the absence of blinding. Expectation effects and differences in perceived engagement may have influenced how participants, especially in the DHA group, reported pain, function, adherence, and medication use. Nevertheless, randomization helps ensure that any general tendency to over- or underreport is equally distributed between groups, thereby preserving internal validity. Given the significant and large clinically relevant between-group differences, we consider the risk of substantially biased results to be low.

Adherence was assessed subjectively through self-reported data collected at the end of the intervention period, introducing the potential for recall bias. Participants may not have accurately remembered or reported the amount of sessions they completed, and responses could have been influenced by social desirability bias. Future studies could consider alternative methods, such as real-time adherence tracking, to improve accuracy. We did not use login data to verify adherence in the IG DHA group because we could not objectively record adherence in the CG SHI-PT group, making a valid comparison impossible. All physiotherapy patients chose their own physiotherapist and made their own appointments. Therefore, it was not economically feasible to objectively collect adherence data for IG SHI-PT. The same applies to the specific therapy content of the sessions received by participants in CG SHI-PT. While German statutory health insurance physiotherapy follows standardized guidelines, individual treatment strategies may vary depending on the treating physiotherapist. This variability limits direct comparability between DHA and SHI-PT. A comparison of physiotherapy administered under standardized ideal conditions and DHA could potentially yield a group difference that is less pronounced than in the present study. However, as our study aimed to evaluate the efficacy of DHA compared to standard care under real-world conditions (intention-to-treat) – rather than comparing digital and face-to-face physiotherapy - this heterogeneity reflects typical clinical practice and supports the external validity of our findings.

Patients who did not respond to either the PRE or POST survey generated missing values. As we conducted the present study according to the intention-to-treat principle, missing values were imputed. In total, only 6 incomplete data sets were available for 253 analyzed patients, which corresponds to 2.4 %. Of these, 5 cases came from CG SHI-PT and 1 from IG DHA. Consequently, the likelihood of systematic bias in the study results due to missing values is minimal. Regardless of the imputation strategy used, the study's findings are likely to be robust against the influence of missing values, given the substantial differences between the treatment arms.

Furthermore, we did not assess participants' prior expertise, experience, or attitudes towards DHAs in general or Mawendo specifically. While participants in the IG had the necessary resources, it remains possible that some faced technological barriers. Additionally, varying levels of digital literacy could influence the ease of use and engagement with the DHA. However, such difficulties would likely bias results in favor of SHI-PT rather than DHA, suggesting that any observed treatment effects were not artificially inflated by technology accessibility. Furthermore, given the increasing integration of digital health solutions in clinical practice, these barriers are expected to diminish over time.

Future Research Directions

While this study provides evidence for the short-term efficacy of DHA-based interventions, future research should investigate their long-term impact. In this regard, one potential advantage of DHAs is that they can be used beyond the prescribed therapy duration, potentially extending their benefits over time. In addition to functional improvements and pain reduction, future studies should explore other clinically relevant endpoints, such as quality of life and additional physical and functional measures (e.g., range of motion, strength, and mobility). These may be particularly relevant for specific populations, such as athletes aiming for an early return to sport or older adults focusing on fall prevention and independence.

DHAs may also have the potential to complement traditional physiotherapy rather than replace it. Their integration into routine care could enhance accessibility, provide continuous support between in-person therapy sessions, and facilitate personalized rehabilitation strategies. Future studies should explore hybrid models that combine DHAs with supervised physiotherapy to optimize patient outcomes. Furthermore, identifying patient subgroups that benefit most from DHA interventions could improve targeted therapy approaches, ensuring more efficient allocation of healthcare

resources. Lastly, investigations into usability aspects may help to further improve the effect of DHAs.

Conclusions

Our findings indicate that the investigated DHA is superior to SHI-PT for treating disorders of the patella. Sex and age did not have any effect on the intervention outcomes of the study. In addition, post treatment pain medication intake was substantially lower for DHA compared to SHI-PT. DHA Mawendo has therefore been approved by BfArM for persons of all sexes aged 12 and over for the treatment of disorders of the patella.

Acknowledgements

We kindly thank all patients for their participation in the study. We thank Lisa C. Peterson for proofreading the revised manuscript and correcting language. The study was sponsored by Mawendo (Mawendo GmbH, Biberach, Germany). Mawendo provided access to DHA for all participants. The sponsor of the study had no role in designing or conducting the study, analyzing or interpreting data, or in writing the manuscript. The trial was designed and conducted by independent academic investigators from the Professorship for Research Methodology and Data Analysis in Biomechanics at the Chemnitz University of Technology.

Author Contributions

TAM: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

DK: Conceptualization, Data curation, Investigation, Methodology, Validation, Visualization, Writing – review & editing.

AKH: Conceptualization, Data curation, Investigation, Methodology, Validation, Visualization, Writing – review & editing.

CM: Conceptualization, Funding acquisition, Investigation, Methodology, Resources, Supervision, Validation, Writing – review & editing.

Conflicts of Interest

The authors declare no conflicts of interests.

Data and Code Availability

Data and R Scripts are available on request due to privacy or other restrictions.

Abbreviations

ADL: activities of daily living

ANCOVA: analysis of covariance

BfArM: Bundesinstitut für Arzneimittel und Medizinprodukte

CG: control group

CONSORT: Consolidated Standards of Reporting Trials

DHA: digital health application

IG: intervention group

KOOS: Knee Injury and Osteoarthritis Outcome Score

MCID: minimal clinically important difference

p: points

P: P-value

POST: survey after completing the treatment period of 12 weeks

PRE: survey before the first therapy session

RCT: randomized controlled trial

Rek-app: browser-based web application created specifically for recruiting purposes provided to the recruiters

SHI-PT: physiotherapy covered by statutory health insurance in Germany

VAS: visual analogue scale

VNRS: verbal numerical rating scale



References

1. Wood L, Muller S, Peat G. The epidemiology of patellofemoral disorders in adulthood: a review of routine general practice morbidity recording. *Primary health care research & development* 2011;12(2):157-164. PMID:21457600
2. Lankhorst NE, Bierma-Zeinstra SMA, van Middelkoop M. Factors associated with patellofemoral pain syndrome: a systematic review. *British Journal of Sports Medicine* 2013;47(4):193-206. PMID:22815424
3. Waryasz GR, McDermott AY. Patellofemoral pain syndrome (PFPS): a systematic review of anatomy and potential risk factors. *Dynamic medicine* : DM 2008;7:9. PMID:18582383
4. Witvrouw E, Werner S, Mikkelsen C, van Tiggelen D, Vanden Berghe L, Cerulli G. Clinical classification of patellofemoral pain syndrome: guidelines for non-operative treatment. *Knee Surg Sports Traumatol Arthrosc* 2005;13(2):122-130. PMID:15703965
5. Bolgla LA, Boling MC. An update for the conservative management of patellofemoral pain syndrome: a systematic review of the literature from 2000 to 2010. *International journal of sports physical therapy* 2011;6(2):112-125.
6. Clijisen R, Fuchs J, Taeymans J. Effectiveness of exercise therapy in treatment of patients with patellofemoral pain syndrome: systematic review and meta-analysis. *Physical therapy* 2014;94(12):1697-1708. PMID:25082920
7. Lack S, Barton C, Sohan O, Crossley K, Morrissey D. Proximal muscle rehabilitation is effective for patellofemoral pain: a systematic review with meta-analysis. *British Journal of Sports Medicine* 2015;49(21):1365-1376. PMID:26175019
8. Xing X, Shi H, Feng S. Does surgical treatment produce better outcomes than conservative treatment for acute primary patellar dislocations? A meta-analysis of 10 randomized controlled trials. *J Orthop Surg Res* 2020;15(1):118. PMID:32209111
9. Loudon JK, Gajewski B, Goist-Foley HL, Loudon KL. The Effectiveness of Exercise in Treating Patellofemoral-Pain Syndrome. *Journal of Sport Rehabilitation* 2004;13(4):323-342. doi:10.1123/jsr.13.4.323
10. Kölle T, Alt W, Wagner D. Effects of a 12-week home exercise therapy program on pain and neuromuscular activity in patients with patellofemoral pain syndrome. *Archives of orthopaedic and trauma surgery* 2020;140(12):1985-1992. PMID:32728976
11. Kettunen JA, Harilainen A, Sandelin J, Schlenzka D, Hietaniemi K, Seitsalo S, Malmivaara A, Kujala UM. Knee arthroscopy and exercise versus exercise only for chronic patellofemoral pain syndrome: a randomized controlled trial. *BMC Med* 2007;5:38. PMID:18078506
12. Kettunen JA, Harilainen A, Sandelin J, Schlenzka D, Hietaniemi K, Seitsalo S, Malmivaara A, Kujala UM. Knee arthroscopy and exercise versus exercise only for chronic patellofemoral pain syndrome: 5-year follow-up. *British Journal of Sports Medicine* 2012;46(4):243-246. PMID:21357578
13. Hadley C, McGrath M, Prodoehl JP, Cohen SB, Emper WD, Hammoud S, Ciccotti MG, Freedman KB, Brahmabhatt S, Mazur DW. Comparison of Traditional Physical Therapy to Internet-Based Physical Therapy after Knee Arthroscopy: A Prospective Randomized Controlled Trial Comparing Patient Outcomes and Satisfaction. *Orthopaedic Journal of Sports Medicine* 2019;7(7_suppl5):2325967119S0034. doi:10.1177/2325967119S00344
14. Tahami M, Vaziri AS, Tahmasebi MN, Ahmadi MA, Akbarzadeh A, Vosoughi F. The functional impact of home-based self-rehabilitation following arthroscopic meniscus root repair. *BMC Musculoskelet Disord* 2022;23(1):753. PMID:35932028
15. Mojica ES, Vasavada K, Hurley ET, Lin CC, Buzin S, Gonzalez-Lomas G, Alaia MJ, Strauss EJ, Jazrawi LM, Campbell KA. Despite Equivalent Clinical Outcomes, Patients Report Less Satisfaction With Telerehabilitation Versus Standard In-Office Rehabilitation After Arthroscopic

- Meniscectomy: A Randomized Controlled Trial. *Arthrosc Sports Med Rehabil* 2023;5(2):e395-e401. PMID:37101883
16. Allen KD, Arbeeva L, Callahan LF, Golightly YM, Goode AP, Heiderscheit BC, Huffman KM, Severson HH, Schwartz TA. Physical therapy vs internet-based exercise training for patients with knee osteoarthritis: results of a randomized controlled trial. *Osteoarthritis Cartilage* 2018;26(3):383-396. PMID:29307722
 17. Klok CJ, Bossen D, Spreeuwenberg PM, Dekker J, Bakker DH de, Veenhof C. Effectiveness of a Blended Physical Therapist Intervention in People With Hip Osteoarthritis, Knee Osteoarthritis, or Both: A Cluster-Randomized Controlled Trial. *Physical therapy* 2018;98(7):560-570. PMID:29788253
 18. Gruner MP, Hogaboom N, Hasley I, Hoffman J, Gonzalez-Carta K, Cheville AL, Li Z, Sellon JL. Prospective, Single-blind, Randomized Controlled Trial to Evaluate the Effectiveness of a Digital Exercise Therapy Application Compared With Conventional Physical Therapy for the Treatment of Nonoperative Knee Conditions. *Arch Rehabil Res Clin Transl* 2021;3(4):100151. PMID:34977534
 19. Jordan JL, Holden MA, Mason EE, Foster NE. Interventions to improve adherence to exercise for chronic musculoskeletal pain in adults. *The Cochrane database of systematic reviews* 2010;2010(1):CD005956. PMID:20091582
 20. Jack K, McLean SM, Moffett JK, Gardiner E. Barriers to treatment adherence in physiotherapy outpatient clinics: a systematic review. *Man Ther* 2010;15(3):220-228. PMID:20163979
 21. Lantzsch H, Eckhardt H, Campione A, Busse R, Henschke C. Digital health applications and the fast-track pathway to public health coverage in Germany: challenges and opportunities based on first results. *BMC Health Serv Res* 2022;22(1):1182. PMID:36131288
 22. Nagel J, Wegener F, Grim C, Hoppe MW. Effects of Digital Physical Health Exercises on Musculoskeletal Diseases: Systematic Review With Best-Evidence Synthesis. *JMIR Mhealth Uhealth* 2024;12:e50616. PMID:38261356
 23. Cottrell MA, Galea OA, O'Leary SP, Hill AJ, Russell TG. Real-time telerehabilitation for the treatment of musculoskeletal conditions is effective and comparable to standard practice: a systematic review and meta-analysis. *Clin Rehabil* 2017;31(5):625-638. PMID:27141087
 24. Wangler J, Jansky M. Two years of approved digital health applications in Germany - Perspectives and experiences of general practitioners with an affinity for their use. *Eur J Gen Pract* 2023;29(1):2186396. PMID:36919621
 25. Kairy D, Lehoux P, Vincent C, Visintin M. A systematic review of clinical outcomes, clinical process, healthcare utilization and costs associated with telerehabilitation. *Disabil Rehabil* 2009;31(6):427-447. PMID:18720118
 26. Uysal İ, Özden F, Özkeskin M, Tümtürk İ, Yucekaya B, Kılınç CY. The Effect of Telehealth-Based Rehabilitation on Patient Reported Outcomes and Objective Clinical Measurements in Patients With Degenerative Meniscal Tear. *Medical Records* 2024;6(2):201-211. doi:10.37990/medr.1419747
 27. Özden F, Sarı Z, Karaman ÖN, Aydoğmuş H. The effect of video exercise-based telerehabilitation on clinical outcomes, expectation, satisfaction, and motivation in patients with chronic low back pain. *Ir J Med Sci* 2022;191(3):1229-1239. PMID:34357527
 28. Huang T, Zhang W, Yan B, Liu H, Girard O. Comparing Telerehabilitation and Home-based Exercise for Shoulder Disorders: A Systematic Review and Meta-analysis. *Arch Phys Med Rehabil* 2024. PMID:38432330
 29. DiGA-Verzeichnis 2024 URL: <https://diga.bfarm.de/de/verzeichnis> [accessed 2024-06-12].
 30. companion patella powered by medi - proved by Dt. Kniegesellschaft, Information für Fachkreise 2025 URL: <https://diga.bfarm.de/de/verzeichnis/00998/fachkreise> [accessed 2025-02-14].
 31. Toelle TR, Utpadel-Fischler DA, Haas K-K, Priebe JA. App-based multidisciplinary back pain treatment versus combined physiotherapy plus online education: a randomized controlled trial.

- Nature Partner Journals Digital Medicine 2019;2(34):34. PMID:31304380
32. Weise H, Zenner B, Schmiedchen B, Benning L, Bulitta M, Schmitz D, Weise K. The Effect of an App-Based Home Exercise Program on Self-reported Pain Intensity in Unspecific and Degenerative Back Pain: Pragmatic Open-label Randomized Controlled Trial. *Journal of medical Internet research* 2022;24(10):e41899. PMID:36215327
 33. Mohan H, Ryan J, Whelan B, Wakai A. The end of the line? The Visual Analogue Scale and Verbal Numerical Rating Scale as pain assessment tools in the emergency department. *Emergency medicine journal* 2010;27(5):372-375. PMID:20442167
 34. R: A language and environment for statistical computing. R. Vienna, Austria; 2019.
 35. Al-Subahi M, Alayat M, Alshehri MA, Helal O, Alhasan H, Alalawi A, Takrouni A, Alfaqeh A. The effectiveness of physiotherapy interventions for sacroiliac joint dysfunction: a systematic review. *Journal of physical therapy science* 2017;29(9):1689-1694. PMID:28932014
 36. Baker RL, Fredericson M. Iliotibial Band Syndrome in Runners: Biomechanical Implications and Exercise Interventions. *Physical Medicine and Rehabilitation Clinics of North America* 2016;27(1):53-77. PMID:26616177
 37. Bartold SJ. The plantar fascia as a source of pain—biomechanics, presentation and treatment. *Journal of Bodywork and Movement Therapies* 2004;8(3):214-226. doi:10.1016/S1360-8592(03)00087-1
 38. Brunner U, Liem D. Rotatorenmanschette. S2e-Leitlinie 2017 URL: https://www.awmf.org/uploads/tx_szleitlinien/033-041l_S2e_Rotatorenmanschette_2017-04_02.pdf [accessed 2023-04-24].
 39. Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale Versorgungsleitlinie Nicht-spezifischer Kreuzschmerz – Langfassung, 2. Auflage. Version 1. 2017. doi:10.6101/AZQ/000353
 40. Chenot J-F, Greitemann B, Kladny B, Petzke F, Pfingsten M, Schorr SG. Non-Specific Low Back Pain. *Deutsches Arzteblatt international* 2017;114(51-52):883-890. PMID:29321099
 41. Ellenbecker TS, Cools A. Rehabilitation of shoulder impingement syndrome and rotator cuff injuries: an evidence-based review. *British Journal of Sports Medicine* 2010;44(5):319-327. PMID:20371557
 42. Fransen M, McConnell S, Harmer AR, van der Esch M, Simic M, Bennell KL. Exercise for osteoarthritis of the knee: a Cochrane systematic review. *British Journal of Sports Medicine* 2015;49(24):1554-1557. PMID:26405113
 43. Fransen M, McConnell S, Hernandez-Molina G, Reichenbach S. Exercise for osteoarthritis of the hip. *The Cochrane database of systematic reviews* 2014;2014(4):CD007912. PMID:24756895
 44. Garving C, Jakob S, Bauer I, Nadjar R, Brunner UH. Impingement Syndrome of the Shoulder. *Deutsches Arzteblatt international* 2017;114(45):765-776. PMID:29202926
 45. Hanratty CE, McVeigh JG, Kerr DP, Basford JR, Finch MB, Pendleton A, Sim J. The effectiveness of physiotherapy exercises in subacromial impingement syndrome: a systematic review and meta-analysis. *Seminars in arthritis and rheumatism* 2012;42(3):297-316. PMID:22607807
 46. Hayden JA, van Tulder MW, Malmivaara A, Koes BW. Exercise therapy for treatment of non-specific low back pain. *The Cochrane database of systematic reviews* 2005;2005(3):CD000335. PMID:16034851
 47. Kroppenstedt S, Halder A. Spezifischer Kreuzschmerz. S2k-Leitlinie 2017 URL: https://www.awmf.org/uploads/tx_szleitlinien/033-051l_S2k_Spezifischer_Kreuzschmerz_2018-02.pdf [accessed 2023-04-24].
 48. Lake DA, Wofford NH. Effect of therapeutic modalities on patients with patellofemoral pain syndrome: a systematic review. *Sports Health* 2011;3(2):182-189. PMID:23016007
 49. Matziolis G. Koxarthrose. S2k-Leitlinie 2019 URL:

- https://register.awmf.org/assets/guidelines/033-001l_S2k_Koxarthrose_2019-07_1_01.pdf [accessed 2023-04-24].
50. Richter M. Aktualisierte Leitlinien Fuß und Sprunggelenk. Fuß & Sprunggelenk 2010;8(4):268-287. doi:10.1016/j.fuspru.2010.08.003
 51. Stöve J. Gonarthrose. S2k-Leitlinie 2017 URL: https://register.awmf.org/assets/guidelines/033-004l_S2k_Gonarthrose_2018-01_1-abgelaufen.pdf [accessed 2023-04-24].
 52. Tischer T. Epicondylopathia radialis humeri, S2k Leitlinie 2019 URL: https://register.awmf.org/assets/guidelines/033-019l_S2k_Epicondylopathia_radialis_humeri_2019-09_01.pdf [accessed 2023-04-24].
 53. Zwiers R, Wiegerinck JI, van Dijk CN. Treatment of midportion Achilles tendinopathy: an evidence-based overview. Knee Surgery, Sports Traumatology, Arthroscopy: official journal of the ESSKA 2016;24(7):2103-2111. PMID:25366192
 54. Aderem J, Louw QA. Biomechanical risk factors associated with iliotibial band syndrome in runners: a systematic review. BioMedCentral Musculoskeletal Disorders 2015;16:356. PMID:26573859
 55. Kessler S, Lang S, Puhl W, Stöve J. Der Knee Injury and Osteoarthritis Outcome Score--ein Funktionsfragebogen zur Outcome-Messung in der Knieendoprothetik. [The Knee Injury and Osteoarthritis Outcome Score--a multifunctional questionnaire to measure outcome in knee arthroplasty]. Zeitschrift für Orthopädie und ihre Grenzgebiete 2003;141(3):277-282. PMID:12822074
 56. Haufe S, Wiechmann K, Stein L, Kück M, Smith A, Meineke S, Zirkelbach Y, Rodriguez Duarte S, Drupp M, Tegtbur U. Low-dose, non-supervised, health insurance initiated exercise for the treatment and prevention of chronic low back pain in employees. Results from a randomized controlled trial. PloS one 2017;12(6):e0178585. PMID:28662094
 57. Lyman S, Lee Y-Y, McLawhorn AS, Islam W, MacLean CH. What Are the Minimal and Substantial Improvements in the HOOS and KOOS and JR Versions After Total Joint Replacement? Clinical orthopaedics and related research 2018;476(12):2432-2441. PMID:30179951
 58. Mecklenburg G, Smittenaar P, Erhart-Hledik JC, Perez DA, Hunter S. Effects of a 12-Week Digital Care Program for Chronic Knee Pain on Pain, Mobility, and Surgery Risk: Randomized Controlled Trial: Randomized Controlled Trial. Journal of medical Internet research 2018;20(4):e156. PMID:29695370
 59. Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health and quality of life outcomes 2003;1(1):64. PMID:14613558
 60. Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hróbjartsson A. Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. BioMedCentral Medicine 2017;15(1):35. PMID:28215182
 61. Ostelo RWJG, Deyo RA, Stratford P, Waddell G, Croft P, Korff M von, Bouter LM, Vet HC de. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine 2008;33(1):90-94. PMID:18165753
 62. R package SampleSize4ClinicalTrials: Sample Size Calculation for the Comparison of Means or Proportions in Phase III Clinical Trials; 2021.
 63. Cro S, Morris TP, Kenward MG, Carpenter JR. Reference-based sensitivity analysis via multiple imputation for longitudinal trials with protocol deviation. The Stata journal 2016;16(2):443-463. PMID:29398978
 64. R package RefBasedMI: Reference-Based Imputation for Longitudinal Clinical Trials with Protocol Deviation; 2023.
 65. R package miceadds: Some Additional Multiple Imputation; 2023.
 66. R: A language and environment for statistical computing. R. Vienna, Austria; 2023.
 67. Altman DG, Matthews JN. Statistics notes. Interaction 1: Heterogeneity of effects. BMJ

- 1996;313(7055):486. PMID:8776324
68. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003;326(7382):219. PMID:12543843
69. Barraclough H, Govindan R. Biostatistics primer: what a clinician ought to know: subgroup analyses. *J Thorac Oncol* 2010;5(5):741-746. PMID:20421767
70. Brankovic M, Kardys I, Steyerberg EW, Lemeshow S, Markovic M, Rizopoulos D, Boersma E. Understanding of interaction (subgroup) analysis in clinical trials. *Eur J Clin Invest* 2019;49(8):e13145. PMID:31135965
71. Cook DI, GebSKI VJ, Keech AC. Subgroup analysis in clinical trials. *Med J Aust* 2004;180(6):289-291. PMID:15012568
72. Matthews JN, Altman DG. Interaction 3: How to examine heterogeneity. *BMJ* 1996;313(7061):862. PMID:8870577
73. Matthews JN, Altman DG. Statistics notes. Interaction 2: Compare effect sizes not P values. *BMJ* 1996;313(7060):808. PMID:8842080
74. Carpenter JR, Roger JH, Kenward MG. Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation. *Journal of biopharmaceutical statistics* 2013;23(6):1352-1371. PMID:24138436
75. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c332. PMID:20332509
76. Devji T, Guyatt GH, Lytvyn L, Brignardello-Petersen R, Foroutan F, Sadeghirad B, Buchbinder R, Poolman RW, Harris IA, Carrasco-Labra A, Siemieniuk RAC, Vandvik PO. Application of minimal important differences in degenerative knee disease outcomes: a systematic review and case study to inform BMJ Rapid Recommendations. *British Medical Journal open* 2017;7(5):e015587. PMID:28495818
77. Hong Q-M, Wang H-N, Liu X-H, Zhou W-Q, Zhang X, Luo X-B. Home-based exercise program and Health education in patients with patellofemoral pain: a randomized controlled trial. *BMC Musculoskelet Disord* 2023;24(1):896. PMID:37980477
78. Nilmar P, Vongsirinavarat M, Khawswan P, Chumthong K, Tadein R, Komalasari DR. Impact of telehealth-based therapeutic exercise on pain, functional performance and dynamic knee valgus in young adult females with patellofemoral pain: a randomised controlled trial. *BMJ Open Sport Exerc Med* 2024;10(4):e001939. PMID:39720152
79. Blønd L, Hansen L. Patellofemoral pain syndrome in athletes: a 5.7-year retrospective follow-up study of 250 athletes. *Acta orthopaedica Belgica* 1998;64(4):393-400. PMID:9922542
80. Collins NJ, Crossley KM, Darnell R, Vicenzino B. Predictors of short and long term outcome in patellofemoral pain syndrome: a prospective longitudinal study. *BioMedCentral Musculoskeletal Disorders* 2010;11(11):11. PMID:20082723
81. Hunt PA, Greaves I. Presentation, examination, investigation and early treatment of acute knee injuries. *Trauma* 2004;6(1):53-66. doi:10.1191/1460408604ta299oa
82. Lau PM-Y, Chow DH-K, Pope MH. Early physiotherapy intervention in an Accident and Emergency Department reduces pain and improves satisfaction for patients with acute low back pain: a randomised trial. *The Australian journal of physiotherapy* 2008;54(4):243-249. PMID:19025504
83. Vickers AJ, Altman DG. Statistics notes: Analysing controlled trials with baseline and follow up measurements. *BMJ* 2001;323(7321):1123-1124. PMID:11701584


Supplementary Files

Untitled.


URL: <http://asset.jmir.pub/assets/e98caa691810b80b8261d841e08be4e2.docx>

Figures


Flow chart of recruitment, randomization, and data collection.




Study flowchart according to CONSORT[60].




PRE – POST comparison of KOOSADL score using notched boxplots (95% CI of median) including mean with 95% CI of the largest imputed effect in CG SHI-PT. Intra-individual positive treatment effects are blue, negative or no effects are red.




PRE – POST comparison of VAS pain score using notched boxplots (95% CI of median) including mean with 95% CI of the largest imputed effect in CG SHI-PT. Intra-individual positive treatment effects are blue, negative or no effects are red.



Relationship between PRE score and treatment success. Differences POST – PRE for both endpoints: A - ‘knee function’, B - ‘knee pain’. IG DHA data are white, CG SHI-PT data are gray.



Treatment success (difference POST – PRE) for both endpoints across all recruiters; A - ‘knee function’ by recruiter. B - ‘knee pain’ by recruiter. IG DHA data are white, CG SHI-PT data are gray.



Multimedia Appendixes

Patient information for adults.

URL: <http://asset.jmir.pub/assets/150b0dc09c4e1795e94731014cfe25f2.pdf>

Patient information for parents of minors.

URL: <http://asset.jmir.pub/assets/09c2c017f7557745da3653a81ab1e43b.pdf>

Patient information for minors.

URL: <http://asset.jmir.pub/assets/4eed24a0f3e5e2b272fa856033fa7838.pdf>

Consort-EHealth v 1.6.1 - Submission_Publication Form.

URL: <http://asset.jmir.pub/assets/4a77a59e4974bc7074fac3bc497f4fbc.pdf>

Screenshots Mawendo ICD-10_M22.

URL: <http://asset.jmir.pub/assets/93276d8e8c5398b9494a7c6079ed6c3f.png>

List of pain medications used.

URL: <http://asset.jmir.pub/assets/2c650d57bee2f9b3b9d1f9a838d31e65.docx>

Mawendo ICD-10_M22 phases and exercises.

URL: <http://asset.jmir.pub/assets/5884e3e535ac6d83e3de4014e37e594b.docx>

Relevant literature for Mawendo ICD-10_M22 exercise compilation.

URL: <http://asset.jmir.pub/assets/92d0b8de26c8a5caca89373cd9b4c73b.pdf>

Related publication(s) - for reviewers eyes onlies

Mawendo ICD-10 M22 systematic literature review.

URL: <http://asset.jmir.pub/assets/b9ce02298f80e8d8fcd4f624a8cb29d3.pdf>

Manuscript with markups.

URL: <http://asset.jmir.pub/assets/7f6da124011d0c0ffcdc05db01a7c117.pdf>